ReAlta Life Sciences Announces New Inflammatory Biomarker Data from Acute Exacerbations of Chronic Obstructive Pulmonary Disease Program at American Thoracic Society 2025 International Conference
NORFOLK, Va.--(BUSINESS WIRE)-- ReAlta Life Sciences, Inc. ('ReAlta' or the 'Company'), a clinical-stage biopharmaceutical company dedicated to saving lives by rebalancing the inflammatory response to address rare and acute inflammatory diseases, today announced a poster presentation featuring new analysis of clinical data from its acute exacerbations of chronic obstructive pulmonary disease (AE-COPD) program at the American Thoracic Society (ATS) 2025 International Conference, taking place May 18-21, 2025 in San Francisco.
The new findings, presented today in a poster titled ' Effect of RLS-0071 on Airway Neutrophilia Following Inhaled Endotoxin Challenge Assessed by ChipCytometry,' were from additional analysis of samples from ReAlta's previously reported Phase 1b study of RLS-0071 (pegtarazimod). Pegtarazimod is a 15-amino-acid peptide that uniquely targets both humoral and cellular inflammation. The analysis, conducted using ChipCytometry, extends the original proof-of-mechanism findings regarding inhibition of lung neutrophils and inflammatory cytokines, and reveals cellular-level mechanisms. Airway neutrophilia is associated with several lung diseases, including acute exacerbations of COPD and severe asthma, and related lung damage is a result of neutrophil-mediated release of toxic myeloperoxidase (MPO) and neutrophil elastase (NE). In this ChipCytometry analysis, pegtarazimod prevented lipopolysaccharide (LPS)-driven increases in neutrophil activation markers (CD89, CD11a, CD11b) as well as intracellular levels of MPO and NE.
In ReAlta's Phase 1b study, healthy participants received inhaled LPS to induce temporary neutrophil-mediated inflammation in the lungs, followed by intravenous administration of pegtarazimod at different dose levels. Pegtarazimod demonstrated powerful inhibition of neutrophil migration into the lungs by half (~50%), with significant reductions in key inflammatory markers including MPO and NE, and pro-inflammatory cytokines IL-1β and IL-8.
'These new data further reinforce pegtarazimod's potential to address neutrophil-driven inflammation in the lungs by meaningfully reducing detrimental neutrophil activation,' said Kenji M. Cunnion, MD, MPH, Chief Medical Officer at ReAlta. 'We look forward to completing our Phase 2 trial in patients with AE-COPD (NCT06175065) later this year and exploring opportunities for our novel dual-targeting peptide platform to deliver effective new therapies for respiratory diseases.'
Prof. Dr. Jens M. Hohlfeld, Division Director of Airway Research at the Fraunhofer Institute for Toxicology and Experimental Medicine in Hannover, Germany and lead investigator for the study, commented, 'ChipCytometry analysis offers various advantages over conventional flow cytometry and differential cell counts that allowed us to visualize how pegtarazimod impacts neutrophil activation markers and intracellular components, which had not been directly observable in our previous analyses. These new insights into pegtarazimod's cellular-level mechanisms of action strengthen the scientific foundation for its development and will inform other upcoming clinical trials in patients with neutrophil-driven inflammatory conditions.'
About ReAlta Life Sciences
ReAlta Life Sciences, Inc. is a clinical mid-stage biopharmaceutical company dedicated to addressing life threatening rare and acute inflammatory diseases by rebalancing the inflammatory response. The Company's EPICC peptide platform leverages discoveries from the human astrovirus (HAstV-1), which uniquely inhibits components of the innate immune system. ReAlta's therapeutic peptides employ the dual-targeting mechanisms of HAstV-1 to modulate both complement and innate inflammatory pathways by inhibiting complement cascade activation and two key neutrophil-driven mechanisms: myeloperoxidase (MPO) and neutrophil extracellular traps (NETs). The Company's lead candidate, RLS-0071 (pegtarazimod), has received FDA Orphan Drug Designation and Fast Track Designations for hypoxic ischemic encephalopathy (HIE), a devastating disease that causes brain damage and high mortality in oxygen-deprived newborns; Orphan Drug Designation by the European Medicines Agency for HIE; FDA Orphan Drug and Fast Track Designations for acute graft-versus-host disease (aGvHD) associated with bone marrow and stem cell transplants; and FDA IND clearance for acute exacerbations of chronic obstructive pulmonary disease (COPD). Founded in 2018, ReAlta operates in Norfolk, Virginia and Aguadilla, Puerto Rico. For more information, please visit www.realtalifesciences.com.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
an hour ago
- Business Wire
CN Bio introduces cross-species DILI services to enhance
CAMBRIDGE, England--(BUSINESS WIRE)--CN Bio, a leading provider of Organ-on-a-chip (OOC) systems and solutions that accelerate drug discovery and development workflows, has introduced two new animal microphysiological system (MPS) models that enhance translatability in preclinical drug safety and toxicology assessments to its Contract Research Services (CRS). Building upon the Company's FDA-recognized drug induced liver injury (DILI) assay, the expanded offering enables rapid, comparative studies between commonly used animal and human models to flag interspecies differences early, and better informs in vivo study design. Traditional human in vitro methods have limited capacity to accurately determine drug toxicity. Added to this, the discrepancies between these methods and in vivo animal studies make it challenging to accurately predict safety risks for humans during preclinical testing. Often, unsafe drug candidates are wrongly progressed, and potentially life-saving ones are misclassified and abandoned, ultimately impacting clinical progression. In response to growing market demand for tools that address these concerns, CN Bio has expanded the in vitro to in vivo extrapolation (IVIVE) capabilities of its established PhysioMimix ® DILI assay, adding the ability to easily compare results across human-, rat-, and dog-derived Liver-on-a-chip models. These assays offer a modernized workflow to generate predictive and actionable insights that mitigate the risk of costly, late-stage conflicting data, and reduce unnecessary animal use by providing early warning of hepatotoxicity/DILI prior to in vivo studies. Accessible through the Company's CRS, the new offering harnesses the longstanding expertise of CN Bio's scientific team to provide detailed data analysis, optimized outcomes, and data-driven conclusions beyond what is achievable using existing in vitro models. The assay enables a broad range of longitudinal and endpoint testing for DILI-specific biomarkers from single- or repeat-dosing studies over a 14-day experimental window. This provides a more comprehensive overview of underlying mechanisms of hepatotoxicity or latent effects of drug candidates to improve IVIVE assessment and streamline clinical progression. Dr Emily Richardson, Lead Scientist, Safety and Toxicology, CN Bio, said: 'Understanding safety risks is critical to successful drug development, however, fundamental physiological and biological differences between species can lead to inaccuracies in predictions, often causing drug candidates to be wrongfully abandoned as toxic, or worse, mistakenly classified as safe.' She added: 'Having established our DILI assay as an industry leading option to garner more valuable insights across the development pipeline, we were in an ideal position to expand its capabilities and address this crucial gap in understanding hepatotoxicity using the most commonly used animal models. Partnering with us to utilize this powerful service not only ensures robust and reliable results but also provides access to a team of Organ-on-a-chip experts, who are invested in your success; to de-risk your pipeline and move it forward with confidence.'
Yahoo
2 hours ago
- Yahoo
Alpha-1 Antitrypsin Deficiency Market Research 2025-2035: Rising Demand for AATD Treatments Fuels Expansion with North America Leading
The global alpha-1 antitrypsin deficiency (AATD) market is expanding, driven by advances in diagnosis, treatment, and growing awareness. Key players like Grifols, CSL Behring, and Pfizer lead innovation. Market growth is fueled by rising disease prevalence and improved therapies but faces high costs. Dublin, June 10, 2025 (GLOBE NEWSWIRE) -- The "Alpha-1 Antitrypsin Deficiency Market - A Global and Regional Analysis: Focus on Treatment, Distribution Channel, and Regional Analysis - Analysis and Forecast, 2025-2035" report has been added to global alpha-1 antitrypsin deficiency (AATD) market is experiencing growth, fueled by advances in diagnosis, treatment options, and increasing awareness of the condition. AATD is a genetic disorder where the body produces insufficient alpha-1 antitrypsin, a protein that protects the lungs and liver. Its deficiency can lead to chronic obstructive pulmonary disease (COPD), emphysema, and liver cirrhosis. The condition often remains underdiagnosed, which presents an opportunity for early detection and primary treatment for AATD is augmentation therapy, which involves the infusion of AAT protein to restore deficient levels in the bloodstream. This therapy is designed to protect the lungs and slow the progression of emphysema. Other treatment options include symptomatic management, such as bronchodilators and corticosteroids. Research continues to explore gene therapies and novel treatments to better address the underlying genetic causes of market is expanding due to rising awareness about AATD, improvements in diagnostic tools, and innovations in treatment options. Key drivers include the increasing prevalence of the disease, particularly in older populations, and the growing availability of specialized therapies. However, challenges such as high treatment costs and the need for long-term care remain significant factors impacting the global alpha-1 antitrypsin deficiency market growth. The North America alpha-1 antitrypsin deficiency market is expected to lead globally due to advanced healthcare infrastructure, high awareness, and significant research investments. The market is primarily driven by augmentation therapy, which involves the administration of alpha-1 proteinase inhibitors to manage disease progression. Enhanced genetic testing and early diagnosis have improved treatment outcomes. Hospitals and specialty clinics serve as key treatment settings, offering specialized care. The region's favorable reimbursement policies and commitment to research and development further support market growth, positioning North America as a dominant force in the global alpha-1 antitrypsin deficiency treatment summary, the global alpha-1 antitrypsin deficiency market is poised for growth, with a strong focus on improving diagnostic accuracy and providing effective treatments, offering significant opportunities for stakeholders in the healthcare and pharmaceutical industries. How Can This Report Add Value to an Organization?Product/Innovation Strategy: Product launches and innovations in the global alpha-1 antitrypsin deficiency market are focused on advancing treatment options to improve patient care. These innovations aim to enhance the efficacy of therapies and streamline the detection and management of the disease. Key players in the global alpha-1 antitrypsin deficiency market, such as Grifols, CSL Behring, Takeda, GlaxoSmithKline plc, and Pfizer Inc., have been involved in offering of therapies for alpha-1 antitrypsin Strategy: Enterprises led by market leaders in the global alpha-1 antitrypsin deficiency market are continuously working on updating their product portfolios with innovative treatments to maintain competitiveness. A detailed competitive benchmarking of the key players in the global alpha-1 antitrypsin deficiency market has been conducted, providing insights into how these companies compare in terms of product offerings, market share, and innovation. This benchmarking provides readers with a clear understanding of the market landscape and the positions of the leading players. Additionally, comprehensive competitive strategies, such as partnerships, agreements, and collaborations, will help readers identify untapped revenue opportunities in the global alpha-1 antitrypsin deficiency Increasing demand for Alpha-1 Antitrypsin Deficiency therapies is anticipated to support the growth of the global alpha-1 antitrypsin deficiency market during the forecast period 2025-2035. The global alpha-1 antitrypsin deficiency market is expected to grow at a significant rate due to advancements in diagnostic technologies, the development of innovative therapies, and increasing awareness among patients and healthcare providers. Recent Developments: Regulatory Activities: In March 2025, Beam Therapeutics announced that the U.S. FDA cleared its Investigational New Drug (IND) application for BEAM-302, a base-editing therapy for AATD. This marks the first clinical advancement of a base-editing approach for AATD, with initial Phase 1/2 trial data showing promising results in correcting the PiZ mutation associated with the disease. Regulatory Activities: In February 2025, Grifols completed enrollment of the second cohort in its Phase 1/2 study for Alpha-1 15%, a subcutaneous AATD treatment. This development could provide patients with a more convenient administration option, enhancing treatment adherence and quality of life. Acquisition: In May 2024, Sanofi completed its acquisition of Inhibrx, Inc., gaining control of INBRX-101, a recombinant human AAT-Fc fusion protein under development for AATD treatment. INBRX-101 aims to normalize serum AAT levels with less frequent dosing, potentially offering a significant advancement in AATD therapy. Market Dynamics The following are the drivers for the global alpha-1 antitrypsin deficiency market: Increasing Awareness and Early Diagnosis Advancements in Treatment Options The global alpha-1 antitrypsin deficiency market is expected to face some limitations too, due to the following challenges: High Treatment Costs Limited Awareness in Emerging Markets Some of the prominent names established in this market are: Grifols CSL Behring Takeda Pharmaceuticals LFB Biotechnologies GlaxoSmithKline plc AstraZeneca Merck Pfizer Inc. Key Topics Covered: Executive SummaryScope and Definition1. Global Alpha-1 Antitrypsin Deficiency Market: Market Outlook1.1 Industry Outlook1.1.1 Market Overview and Ecosystem1.1.2 Market Trends1.1.3 Epidemiological Analysis of Alpha-1 Antitrypsin Deficiency1.1.3.1 By Region1.1.4 Clinical Trials1.1.4.1 By Phase1.1.4.2 By Sponsor Type1.1.5 Regulatory Landscape / Compliance1.1.5.1 Legal Requirement and Framework in the U.S.1.1.5.2 Legal Requirement and Framework in the E.U.1.1.5.3 Legal Requirement and Framework in Japan1.1.5.4 Legal Requirement and Framework in Rest-of-the-World1.2 Market Dynamics1.2.1 Impact Analysis1.2.2 Market Drivers1.2.3 Market Restraints1.2.4 Market Opportunities2. Global Alpha-1 Antitrypsin Deficiency Market, By Treatment, $Million, 2023-20352.1 Overview2.2 Augmentation Therapy2.3 Bronchodilators2.4 Corticosteroids2.5 Oxygen Therapy3. Global Alpha-1 Antitrypsin Deficiency Market, By Distribution Channel, $Million, 2023-20353.1 Overview3.2 Hospitals Pharmacy3.3 Retail Pharmacies3.4 Online Pharmacies4. Global Alpha-1 Antitrypsin Deficiency Market, By Region, $Million, 2023-20354.1 North America4.1.1 Key Findings4.1.2 Market Dynamics4.1.3 Market Sizing and Forecast4.1.3.1 North America Alpha-1 Antitrypsin Deficiency Market (by Distribution Channel)4.1.3.2 North America Alpha-1 Antitrypsin Deficiency Market (by Country)4.1.3.2.1 U.S.4.1.3.2.2 Canada4.2 Europe4.2.1 Key Findings4.2.2 Market Dynamics4.2.3 Market Sizing and Forecast4.2.3.1 Europe Alpha-1 Antitrypsin Deficiency Market (by Distribution Channel)4.2.3.2 Europe Alpha-1 Antitrypsin Deficiency Market (by Country)4.3 Asia-Pacific4.4 Rest-of-the-World5. Global Alpha-1 Antitrypsin Deficiency Market - Competitive Landscape and Company Profiles5.1 Competitive Landscape5.1.1 Growth Share Matrix (2024)5.1.1.1 By Treatment5.1.2 Key Strategies and Developments by Company5.1.2.1 Funding Activities5.1.2.2 Mergers and Acquisitions5.1.2.3 Regulatory Approvals5.1.2.4 Partnerships, Collaborations and Business Expansions5.1.3 Key Developments Analysis5.2 Company Profiles5.2.1 Company Overview5.2.2 Product Portfolio5.2.3 Target Customers/End Users5.2.4 Analyst View6. Research Methodology For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
3 hours ago
- Business Wire
Emulate Launches AVA™ Emulation System to Accelerate Drug Development With First-of-its-Kind High-Throughput Organ-Chip Platform
BOSTON--(BUSINESS WIRE)--Emulate, Inc., the world leader in Organ-on-a-Chip technology, today announced the commercial launch of the AVA™ Emulation System, a self-contained instrument that cultures, incubates, and images up to 96 independent Organ-Chip samples in a single run. AVA delivers an unprecedented magnitude of in vivo -level insights faster than animal models while cutting consumable costs four-fold and in-lab labor by half compared to current generation technologies. These transformative capabilities give the pharmaceutical industry the practical means to pivot beyond animal testing and into truly human-relevant territory. With the FDA targeting animal studies to become 'the exception rather than the norm,' the need for proven human models is urgent. Emulate's Liver-Chip S1—the first and only Organ-Chip admitted to the FDA's ISTAND program. Share 'AVA gives scientists unprecedented experimental capacity with the biological depth of live human tissue—something no other platform can match,' said Jim Corbett, Chief Executive Officer at Emulate. 'By combining Emulate's proven Organ-on-a-Chip technology with high-throughput consumables, automated imaging, and streamlined workflows in one benchtop unit, AVA lets teams ask bigger questions earlier and move the right drug candidates forward faster.' AVA Emulation System: Three Instruments in One AVA is the first self-contained Organ-on-a-Chip workstation to fuse high-throughput microfluidic tissue culture, full environmental control, and real-time imaging into a single, compact benchtop unit. Key performance gains include: Expanded experimental power – 96 independent Organ-Chip samples in a single run enable researchers to achieve microplate-level scale of their Organ-Chip experiments, enabling side-by-side comparison of dozens of compounds, doses, or stimuli. Lower operating costs – AVA achieves a four-fold drop in consumable spend and up to 50% fewer cells and media per sample compared to previous generation technology. Time & labor savings – Hands-on, in-lab time is reduced by more than half, thanks to automated microscopy, remote monitoring, and the revolutionary new Chip-Array™ consumable that integrates 12 independent Organ-Chips into an SBS format for streamlined workflows with multichannel pipettes and automated liquid handlers. AI-ready datasets – A typical 7-day experiment can generate >30,000 time-stamped data points from daily imaging and effluent assays, with post-takedown omics pushing the total into the millions—providing a rich, multi-modal foundation to feed machine-learning pipelines for target discovery, lead optimization, and safety prediction. A Timely Answer to Shifting Regulations With the FDA targeting animal studies to become 'the exception rather than the norm,' the need for proven human models is urgent. Emulate's Liver-Chip S1—the first and only Organ-Chip admitted to the FDA's ISTAND program—has already outperformed animals, showing 87% sensitivity and 100% specificity for drug-induced liver injury in a 2022 Communications Medicine study. AVA now scales that level of human relevance across discovery, efficacy, and toxicology screens, accelerating safer therapies through the pipeline. 'Moving towards reduction and in some cases replacement of animal models demands both biological fidelity and throughput,' noted Dr. Lorna Ewart, Emulate Chief Scientific Officer. 'AVA meets those dual requirements, empowering teams to rank-order lead candidates, pinpoint off-target toxicities, and advance safer therapies with unprecedented speed and confidence.' Broad Impact Across Industries In biopharma, this type of reduction and replacement is already a reality. A leading pharmaceutical company has demonstrated the power of implementing Organ-Chips into their development pipeline when one of their scientists saved millions of dollars and years of development time by using Emulate Liver-Chips ahead of non-human primates to screen lipid-nanoparticle (LNP) candidates. AVA's leap in throughput of predictive human biology stands to benefit not only biopharma but a wide spectrum of sectors that currently rely on inaccurate animal testing. Large pharmaceutical pipelines can now run comparable screens in a single AVA experiment, while smaller biotech teams gain enterprise-level capacity without adding headcount or infrastructure. Beyond therapeutics, contract research organizations, consumer-product companies, and environmental agencies can harness AVA to evaluate industrial chemicals, food additives, and cosmetic ingredients under human-relevant conditions—bringing faster, more ethical safety and efficacy decisions to market-driven and regulatory programs alike. Availability Global orders are open immediately. For pricing or demonstrations, please submit a request here. About Emulate Emulate, Inc. is the pioneer of Organ-on-a-Chip technology, enabling researchers to accurately replicate human tissue function and disease biology through next generation in vitro models. From target discovery to IND submission, Emulate aims to ignite a new era in human health research—one that reduces animal testing, cuts drug development costs, and accelerates the delivery of life-saving treatments. Emulate's Organ-Chip platforms, consumables, and organ models help the world's leading pharmaceutical, biotech, and academic teams generate human-relevant data that advance safer, more effective therapies. Learn more at
